Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The Multiple Myeloma Research Foundation (MMRF) CoMMpass SM Study: A Longitudinal Study in Newly-Diagnosed Multiple Myeloma Patients to Assess Genomic Profiles, Immunophenotypes and Clinical Outcomes

Michael N. Needle, MD, Beverly Harrison, Carolyn Hoban, DSc, Pamela G. Kidd, MD, Scott Jewell, PhD, Thomas Monroe, PhD, Jonathan J Keats, PhD, John Carpten, PhD, Louise M. Perkins, PhD, Kenneth Anderson, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 3980.

https://doi.org/10.1182/blood.V120.21.3980.3980

Published: 2012

Journal Articles

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6

Rodger E. Tiedemann, Yuan Xiao Zhu, Jessica Schmidt, Hongwei Yin, Chang-Xin Shi, Qiang Que, Gargi Basu, David Azorsa, Louise M. Perkins, Esteban Braggio, Rafael Fonseca, P. Leif Bergsagel, Spyro Mousses, A. Keith Stewart

Blood (2010) 115 (8): 1594–1604.

https://doi.org/10.1182/blood-2009-09-243980

Published: 2010

Includes: Supplemental data

Journal Articles

HOXA9 Is a Novel Therapeutic Target in Multiple Myeloma.

Michael A Chapman, Jean-Philippe Brunet, Jonathan J Keats, PhD, Angela Baker, Mazhar Adli, Anna C. Schinzel, Gregory Ahmann, BS, Harview Christina, Anna Moore, Vijayalakshmi Shanmugam, Louise M. Perkins, PhD, Daniel Auclair, PhD, William C. Hahn, MD, PhD, Bradley E. Bernstein, MD, Leif Bergsagel, Rafael Fonseca, John Carpten, Jeffrey Trent, Todd R. Golub, MD

Blood (2009) 114 (22): 832.

https://doi.org/10.1182/blood.V114.22.832.832

Published: 2009

Journal Articles

Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1.

Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Yuan Xiao Zhu, Jessica Schmidt, BS, Hongwei Yin, PhD, Quick Que, PhD, David Azorsa, PhD, Louise M. Perkins, PhD, Esteban Braggio, PhD, Craig B. Reeder, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Spyro Mousses, PhD, A. Keith Stewart, MD

Blood (2009) 114 (22): 601.

https://doi.org/10.1182/blood.V114.22.601.601

Published: 2009

Journal Articles

CpG Methylation Profiling in Multiple Myeloma.

Bodour Salhia, PhD, Angela Baker, PhD, Jonathan J Keats, PhD, Gregory Ahmann, BS, Daniel Auclair, PhD, Bunmi Mfuko, Louise M. Perkins, PhD, Joan Levy, PhD, Leif Bergsagel, MD, Rafael Fonseca, MD, John Carpten, PhD

Blood (2009) 114 (22): 604.

https://doi.org/10.1182/blood.V114.22.604.604

Published: 2009

Journal Articles

Interim Analyses of the MMRC Reference Collection Identifies Recurrent Genomic-Level Events in Multiple Myeloma and Demonstrates That CDKN2C/p18 Deletion Is the Pre-Eminent Copy Number Alteration in Poor Prognosis Disease

Michael A Chapman, Jean-Philippe Brunet, Angela Baker, Jonathan Keats, Gregory Ahmann, BS, Anna C Schinzel, PhD, Anna Moore, Vijayalakshmi Shanmugam, Louise M. Perkins, PhD, Daniel Auclair, PhD, William C. Hahn, M.D., Ph.D, P. Leif Bergsagel, MD, Rafael Fonseca, MD, John Carpten, Jeffrey Trent, Todd R. Golub, MD

Blood (2008) 112 (11): 497.

https://doi.org/10.1182/blood.V112.11.497.497

Published: 2008

Journal Articles

The Multiple Myeloma Research Consortium Genomics Initiative.

Jeffrey Trent, PhD, John Carpten, PhD, Michael Reich, PhD, Ted Liefeld, PhD, Jonathan Keats, PhD, Spyro Mousses, PhD, William Hahn, MD, PhD, Suzanne Trudel, MD, David Siegel, PhD, S. Vincent Rajkumar, MD, Melissa Alsina, MD, Paul Richardson, MD, Kenneth Anderson, MD, Daniel Auclair, PhD, Louise M. Perkins, PhD, Kathy Giusti, Rafael Fonseca, MD, Todd R. Golub, MD

Blood (2007) 110 (11): 2498.

https://doi.org/10.1182/blood.V110.11.2498.2498

Published: 2007

Journal Articles

Genomc-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.

Jonathan Keats, PhD, Mike Chapman, PhD, John Carpten, PhD, Wee-Joo Chng, MD, Angela Baker, PhD, Gregory Ahmann, Suzanne Trudel, MD, David Siegel, MD, PhD, S. Vincent Rajkumar, MD, Melissa Alsina, MD, Paul Richardson, MD, Kenneth Anderson, MD, Daniel Auclair, PhD, Louise M. Perkins, PhD, Jeffrey Trent, PhD, Todd R. Golub, MD, Rafael Fonseca, MD

Blood (2007) 110 (11): 396.

https://doi.org/10.1182/blood.V110.11.396.396

Published: 2007

NARROW

The Multiple Myeloma Research Foundation (MMRF) CoMMpass SM Study: A Longitudinal Study in Newly-Diagnosed Multiple Myeloma Patients to Assess Genomic Profiles, Immunophenotypes and Clinical Outcomes

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6

HOXA9 Is a Novel Therapeutic Target in Multiple Myeloma.

Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1.

CpG Methylation Profiling in Multiple Myeloma.

Interim Analyses of the MMRC Reference Collection Identifies Recurrent Genomic-Level Events in Multiple Myeloma and Demonstrates That CDKN2C/p18 Deletion Is the Pre-Eminent Copy Number Alteration in Poor Prognosis Disease

The Multiple Myeloma Research Consortium Genomics Initiative.

Genomc-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only